Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:21 PM
Ignite Modification Date:
2026-03-26 @ 3:21 PM
NCT ID:
NCT05679427
Eligibility Criteria:
Inclusion Criteria:
* Performance status ECOG ≤2
* Life expectancy \> 6 months according to Mizumoto criteria\*
* Oligometastatic disease (Total number of metastases from 1 to 5: both synchronous and metachronous with maximum involvement of three organs in total - lymph nodes, bones, lungs, liver, adrenal gland, brain- with known histology
* At least one bone metastasis treatable with SABR or SRS
* Each secondary localization (synchronous, metachronous or oligoprogressive) must be treated with radical intent.
* Patients may have received other anticancer treatments (surgery for initial site of disease or other metastases, chemotherapy, radiotherapy for other metastatic sites)
Exclusion Criteria:
* Sites of disease not eligible for stereotactic radiotherapy
* Serious medical comorbidities that preclude RT
* Overlap with a previously treated volume of radiotherapy
* Dimension greater than 5 cm for extra-cranial lesions.
* Size greater than 3 cm for brain lesions
* More than 1 brain metastases
* Clinical or radiological evidence of spinal cord compression or epidural tumor within 2mm of the spinal cord
* Radiological evidence of vertebral body fracture or involvement of more than 40% of the vertebral body
* Radiological evidence of cortical involvement in long bones
* Pregnant or breastfeeding women
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
85 Years
Study:
NCT05679427
Study Brief:
Protocol Section:
NCT05679427